826 related articles for article (PubMed ID: 30570368)
1. Ocrelizumab for the treatment of multiple sclerosis.
Bigaut K; De Seze J; Collongues N
Expert Rev Neurother; 2019 Feb; 19(2):97-108. PubMed ID: 30570368
[TBL] [Abstract][Full Text] [Related]
2. Ocrelizumab: A Review in Multiple Sclerosis.
Lamb YN
Drugs; 2022 Feb; 82(3):323-334. PubMed ID: 35192158
[TBL] [Abstract][Full Text] [Related]
3. Ocrelizumab Depletes CD20⁺ T Cells in Multiple Sclerosis Patients.
Gingele S; Jacobus TL; Konen FF; Hümmert MW; Sühs KW; Schwenkenbecher P; Ahlbrecht J; Möhn N; Müschen LH; Bönig L; Alvermann S; Schmidt RE; Stangel M; Jacobs R; Skripuletz T
Cells; 2018 Dec; 8(1):. PubMed ID: 30597851
[TBL] [Abstract][Full Text] [Related]
4. Ocrelizumab: its efficacy and safety in multiple sclerosis.
Juanatey A; Blanco-Garcia L; Tellez N
Rev Neurol; 2018 Jun; 66(12):423-433. PubMed ID: 29897610
[TBL] [Abstract][Full Text] [Related]
5. Two cases of meningitis associated with ocrelizumab therapy.
Theriault M; Solomon AJ
Mult Scler Relat Disord; 2020 Feb; 38():101866. PubMed ID: 31821962
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY).
Chisari CG; Bianco A; Brescia Morra V; Calabrese M; Capone F; Cavalla P; Chiavazza C; Comi C; Danni M; Filippi M; Iaffaldano P; Lanzillo R; Lo Fermo S; Lucisano A; Lugaresi A; Lus G; Marfia GA; Marinelli F; Mirabella M; Moiola L; Perin C; Realmuto S; Toscano S; Trojano M; Vecchio D; Patti F;
Neurotherapeutics; 2023 Oct; 20(6):1696-1706. PubMed ID: 37610702
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
Manchon E; Laplaud D; Vukusic S; Labauge P; Moreau T; Kobelt G; Grouin JM; Lotz M; Pau D; Christine LF
Mult Scler Relat Disord; 2022 Dec; 68():104109. PubMed ID: 36007299
[TBL] [Abstract][Full Text] [Related]
8. A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues.
Frisch ES; Pretzsch R; Weber MS
Neurotherapeutics; 2021 Jul; 18(3):1602-1622. PubMed ID: 33880738
[TBL] [Abstract][Full Text] [Related]
9. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis.
McCool R; Wilson K; Arber M; Fleetwood K; Toupin S; Thom H; Bennett I; Edwards S
Mult Scler Relat Disord; 2019 Apr; 29():55-61. PubMed ID: 30677733
[TBL] [Abstract][Full Text] [Related]
10. Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts - the CONFIDENCE study protocol.
Dirks P; Zingler V; Leemhuis J; Berthold H; Hieke-Schulz S; Wormser D; Ziemssen T
BMC Neurol; 2020 Mar; 20(1):95. PubMed ID: 32171264
[TBL] [Abstract][Full Text] [Related]
11. Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study.
Pontieri L; Blinkenberg M; Bramow S; Papp V; Rasmussen PV; Kant M; Schäfer J; Mathiesen HK; Jensen MB; Sirakov G; Berg JM; Kopp TI; Joensen H; Sellebjerg F; Magyari M
Eur J Neurol; 2022 Feb; 29(2):496-504. PubMed ID: 34644452
[TBL] [Abstract][Full Text] [Related]
12. Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis.
Menge T; Dubey D; Warnke C; Hartung HP; Stüve O
Expert Rev Neurother; 2016 Oct; 16(10):1131-9. PubMed ID: 27552111
[TBL] [Abstract][Full Text] [Related]
13. Ocrelizumab in highly disabled progressive multiple sclerosis patients.
Houtchens M; Howard D
Mult Scler Relat Disord; 2024 Feb; 82():105345. PubMed ID: 38181693
[TBL] [Abstract][Full Text] [Related]
14. B cell depletion in the treatment of multiple sclerosis.
Myhr KM; Torkildsen Ø; Lossius A; Bø L; Holmøy T
Expert Opin Biol Ther; 2019 Mar; 19(3):261-271. PubMed ID: 30632834
[TBL] [Abstract][Full Text] [Related]
15. Dengue fever in a multiple sclerosis patient taking Ocrelizumab.
Guerra T; Bollo L; Trojano M; Iaffaldano P
Mult Scler; 2021 Nov; 27(13):2116-2118. PubMed ID: 34449289
[TBL] [Abstract][Full Text] [Related]
16. Ocrelizumab: a B-cell depleting therapy for multiple sclerosis.
Jakimovski D; Weinstock-Guttman B; Ramanathan M; Kolb C; Hojnacki D; Minagar A; Zivadinov R
Expert Opin Biol Ther; 2017 Sep; 17(9):1163-1172. PubMed ID: 28658986
[TBL] [Abstract][Full Text] [Related]
17. Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population.
Fernandez-Diaz E; Perez-Vicente JA; Villaverde-Gonzalez R; Berenguer-Ruiz L; Candeliere Merlicco A; Martinez-Navarro ML; Gracia Gil J; Romero-Sanchez CM; Alfaro-Saez A; Diaz I; Gimenez-Martinez J; Mendez-Miralles MA; Millan-Pascual J; Jimenez-Pancho J; Mola S; Sempere AP
Ann Clin Transl Neurol; 2021 Feb; 8(2):385-394. PubMed ID: 33369288
[TBL] [Abstract][Full Text] [Related]
18. Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness.
Barun B; Gabelić T; Adamec I; Babić A; Lalić H; Batinić D; Krbot Skorić M; Habek M
Mult Scler Relat Disord; 2021 Feb; 48():102704. PubMed ID: 33370649
[TBL] [Abstract][Full Text] [Related]
19. Ocrelizumab: A New B-cell Therapy for Relapsing Remitting and Primary Progressive Multiple Sclerosis.
Stahnke AM; Holt KM
Ann Pharmacother; 2018 May; 52(5):473-483. PubMed ID: 29232960
[TBL] [Abstract][Full Text] [Related]
20. Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis.
Cellerino M; Boffa G; Lapucci C; Tazza F; Sbragia E; Mancuso E; Bruschi N; Minguzzi S; Ivaldi F; Poirè I; Laroni A; Mancardi G; Capello E; Uccelli A; Novi G; Inglese M
Neurotherapeutics; 2021 Oct; 18(4):2579-2588. PubMed ID: 34553320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
